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Summary 
 
N4-Behenoyl-1-β-D-arabinofuranosylcytosine (BHAC), a prodrug of 
1-β-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in 
Japan.  BHAC therapy may be more effective if it is directed by 
1-β-D-arabinofuranosylcytosine 5’-triphosphate (ara-CTP), the intracellular active 
metabolite of ara-C derived from BHAC.  However, previous monitoring methods for 
ara-CTP were less sensitive.  Here, using our new sensitive method, we evaluated the 
ara-CTP pharmacokinetics viewing from the therapeutic response in 11 acute 
myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg/m2) in the 
combination remission induction therapy.  ara-CTP at low levels under 1 μM could be 
monitored.  BHAC kept both the plasma ara-C and the intracellular ara-CTP for a 
longer time, even compared with the historical values of high-dose ara-C.  The area 
under the concentration-time curve of ara-CTP was significantly greater in the patients 
with complete remission than in the patients without the response.  This greater 
amount of ara-CTP was attributed to the higher ara-CTP concentrations achieved in the 
responding patients.  There was no difference of the plasma ara-C pharmacokinetics 
between the two groups.  Thus, for the first time in BHAC therapy, the ara-CTP 
pharmacokinetics was evaluated in relation to the therapeutic effect, and the importance 
of ara-CTP was clinically shown.  The optimal BHAC therapy may be directed by the 
ara-CTP pharmacokinetics in each individual patient. 
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INTRODUCTION 
 
   1-β-D-Arabinofuranosylcytosine (ara-C) is one of the most effective anticancer 
agents in the treatment of leukemia.1-3)  The administration of ara-C at a conventional 
dose in combination with other antileukemic drugs has markedly improved remission 
rates of the induction therapy for acute myelogenous leukemia (AML).1-3)  As the 
mechanism of action, after being transported into leukemic cells, ara-C is 
phosphorylated to 1-β-D-arabinofuranosylcytosine 5'-monophosphate and then to its 
active metabolite, 1-β-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP).4)  
ara-CTP inhibits DNA polymerases in competition with deoxycytidine 5'-triphosphate.5-7)  
A small portion of ara-CTP is incorporated into the DNA strand and terminates the DNA 
elongation.8)  Consequently, ara-C exerts its cytotoxic effect by inhibiting DNA 
synthesis.  Therefore, the intracellular ara-CTP is a key metabolite for the mechanism 
of action,5-8) and the cytotoxicity of ara-C is S phase-specific and time-dependent.9)
   While the cytotoxic effect of ara-C is time-dependent, the drug is rapidly inactivated 
to 1-β-D-arabinofuranosyuracil by cytidine deaminase in the plasma.4, 10)  To overcome 
this dilemma, several derivatives of ara-C, which are long-acting or deaminase-resistant, 
has been evaluated.11-14)  N4-Behenoyl-1-β-D-arabinofuranosylcytosine (BHAC) is one 
of the acyl derivatives of ara-C, which has a long-chain fatty acyl group at the 4-amino 
position of ara-C ,11, 12)  and thereby is resistant to inactivation by cytidine 
deaminase.12)  BHAC was proved to exhibit its cytotoxicity on various experimental 
tumors regardless of the treatment schedules, mainly because of its resistance to 
deamination.11, 12)  Clinically, for over 15 years in Japan, BHAC has been used 
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effectively in the combination remission induction therapy for AML patients, and 
provided over 70% remission rates.15-17)
   The mechanism of action in BHAC is thought to be substantially the same as is seen 
in ara-C.18)  In the plasma, BHAC is converted into ara-C by ω- and β-oxidation of the 
acyl moiety, and the resultant ara-C is transported into leukemic cells.11, 12, 18)  In the 
cells, the subsequent ara-C is phosphorylated to ara-CTP thereafter.  Again, ara-CTP 
is thought to be a key metabolite for the cytotoxic effect.18)   
   The importance of ara-CTP has been already shown clinically in high-dose ara-C 
therapies by Plunkett et al.19, 20)  They demonstrated that ara-CTP was not predicted by 
the plasma ara-C pharmacokinetics, and that the therapeutic efficacy was closely 
correlated to the amount of ara-CTP.  On the other hand, the significance of ara-CTP 
was seldom described in the conventional-dose ara-C or BHAC therapy because the 
previous detection methods for ara-CTP were less sensitive.21)   
   There are several reports on the pharmacokinetic study of BHAC, including 
ours.22-24)  We have already reported the pharmacokinetics of the plasma BHAC and 
the plasma ara-C as a metabolite of BHAC, during a 90-min intravenous infusion of 
conventional-dose BHAC.24)  In that study, BHAC was well maintained in the plasma 
and, at the same time, it was converted into ara-C slowly.  Consequently, the plasma 
ara-C concentration was maintained continuously by BHAC administration.  We proved 
that this deaminase-resistant prodrug worked as a long-acting ara-C.24)
   If the intracellular ara-CTP is monitored simultaneously during BHAC therapy, the 
pharmacokinetic study may be more informative because the active metabolite of BHAC 
is ara-CTP.  Furthermore, if the importance of ara-CTP is clinically demonstrated from 
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the viewpoint of the therapeutic efficacy of BHAC, the optimal BHAC therapy may be 
constructed based on the understanding of the ara-CTP pharmacokinetics.   
   Recently, we successfully monitored ara-CTP in leukemic cells of AML patients 
receiving low- or conventional- dose ara-C or BHAC by means of our new sensitive 
determination method.25, 26)  In that preliminary report, we referred to the future 
direction that we would evaluate the relationship between the ara-CTP 
pharmacokinetics and the therapeutic outcome.26)  Thus, in the present study,  we 
integrated new patients and evaluated the ara-CTP pharmacokinetics viewing from the 
therapeutic response in AML patients receiving conventional-dose BHAC in the 
combination remission induction therapy.     
 
MATERIALS AND METHODS 
 
Chemicals and enzymes  ara-C, ara-CTP and bacterial alkaline phosphatase (EC 
3.1.3.1) were purchased from Sigma Chemical Co. (St. Louis, MO, USA).  Na2HPO4, 
acetonitrile, NaCl, Tris, perchloric acid, KOH, and dextran were purchased from Nacalai 
Tesque. Inc. (Kyoto).  Tetrahydrouridine was obtained from Calbiochem-Novabiochem 
Corp. (La Jolla, CA, USA).  Charcoal was purchased from J. T. Baker Chemical Co. 
(Phillipsburg, NJ, USA).  [5-3H]-ara-C (30 Ci/mmol) was purchased from Amersham 
International (Buckinghamshire, UK).  Anti-ara-C serum was kindly supplied by Asahi 
Chemical Industry Co., Ltd. (Tokyo).27)
Patients and treatments  Eleven patients eligible for the pharmacological studies 
were diagnosed as having AML (M1; 2 patients, M2; 7 patients, M4; 2 patients by 
- 5 –  
  
French-American-British classification) by the standard hematological and clinical 
criteria confirmed by the examination of bone marrow.  They were 5 males and 6 
females.  Median age was 65 (range; 35-83).  Informed consent for this investigation 
was obtained in advance.  BHAC at 70 mg/m2 was administered by intravenous 
infusion for 2 h twice daily in combination with 6-mercaptopurine (70 mg/m2), etoposide 
(70 mg/m2) and idarubicin (12 mg/m2) as remission induction therapy.3)  Complete 
remission (CR) was considered established when blasts became less than 5% with 
normal levels of granuloid and erythroid series in bone marrow, and with normal levels 
of peripheral leukocytes and platelets.   
Sample collection  Blood samples were obtained before the therapy and after 0, 1, 2, 
4, 6 and 10 h from the end of BHAC administration.  The blood samples were then put 
into heparinized tubes containing tetrahydrouridine, an inhibitor of cytidine deaminase, 
at a final concentration of 0.1 mM.28)  The plasma and the mononuclear cells including 
leukemic blasts were fractionated by a Ficoll-Paque density centrifugation procedure.29)  
Both the plasma ara-C concentration and the ara-CTP concentration in leukemic cells 
were measured.  In this study, we did not measure the plasma BHAC concentration 
because it was emphasized as a primary focus in our previous study.24)
Determination of the plasma ara-C concentration  The plasma ara-C concentration 
was measured using the radioimmunoassay described by Shimada et al. with minor 
modifications.27)  In brief, 50 µl of the plasma was mixed with 200 µl of 0.01 M 
phosphate buffer (containing 0.5% bovine serum albumin and 0.9% NaCl, pH 7.4), 50 µl 
of anti-ara-C serum, and 50 µl of [5-3H]-ara-C.  The mixture was incubated for 16 h at 
4 °C.  Five hundred microliters of dextran-coated charcoal, which was composed of 
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100 mg of dextran and 1,000 mg of charcoal per 100 ml of the above phosphate buffer, 
was added to the mixture.  The mixture was allowed to stand for 30 min at 4 °C, and 
centrifuged (1,000 x g, 15 min, 4 °C).  The radioactivity of the supernatant was 
determined.  The detection limit was 0.4 nM.  
Determination of the intracellular ara-CTP concentration  The intracellular 
ara-CTP concentration was determined by the newly established method we previously 
reported.25)  The nucleotide pool including ara-CTP was extracted from leukemic cells 
(2 x 107 cells) using cold perchloric acid (final concentration 0.3 M), and then 
neutralized by KOH.  ara-CTP was separated from the other nucleotides by 
high-performance liquid chromatography with an ion-exchange column, TSK gel 
DEAE-2 SW (250 x4.6 mm inside diameter: particle size 5 µl: TOSOH Corp., Tokyo).  
The elution was performed with 0.05 M Na2HPO4 (pH 6.9) - 20% acetonitrile at a 
constant flow rate of 0.7 ml/min at an ambient temperature.  ara-CTP was monitored at 
269 nm.  The ara-CTP fraction was freeze-dried, dissolved again in 300 µl of 0.1 M 
Tris buffer (pH 10.1), and mixed with alkaline phosphatase (10 units).  The mixture 
was incubated for 12 h at 55 °C, with the result that ara-CTP was dephosphorylated to 
ara-C.  The ara-C derived from ara-CTP was measured using the radioimmunoassay 
described above.  The obtained value of ara-CTP was divided by the packed cell 
volume occupied by the cell number (2 x 107 cells) to determine the intracellular 
concentration.  The detection limit was 20 nM. 
Pharmacokinetic analysis  The area under the concentration-time curve from 0 to 24 
h (AUC) and the pharmacokinetic parameters were obtained by moment analysis.30)  
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RESULTS 
 
   Our new sensitive method enabled the measurement of the low ara-CTP 
concentrations under 1 µM.  The mean ± SD concentration-time curves of the plasma 
ara–C and the intracellular ara-CTP of all the patients are shown in Fig. 1.  The 
pharmacokinetic parameters (mean ± SD values) are summarized in Table I.   
Pharmacokinetics of the plasma ara-C and the intracellular ara-CTP  The plasma 
ara-C reached the maximal concentration (Cmax) at the end of the infusion and 
decreased gradually thereafter.  The intracellular ara-CTP reached the Cmax at 4 h from 
the end of the infusion and was eliminated gradually thereafter.  The coefficient of 
variation of the Cmax, the elimination half-life (t1/2) and the AUC for ara-CTP were 74, 52, 
and 46%, respectively.  Thus, the intracellular pharmacokinetics widely varied among 
patients.  The Cmax and the AUC of the intracellular ara-CTP were not predicted from 
the respective parameters of the plasma ara-C (Fig. 2) (p=0.79 for the Cmax, p=0.66 for 
the AUC, Spearman’s correlation test).   
The comparison of the pharmacokinetics between CR and no response (NR) 
groups  Seven patients reached CR (CR group) while 4 did not respond to the 
treatment (NR group).  The total dose of BHAC administered to each patient during the 
induction therapy was 1182 ± 250 mg/m2 (mean ± SD) in CR group, and 1026 ± 80 
mg/m2 in NR group.  Thus, there was no difference between the total doses in the two 
groups (p=0.42, Mann-Whitney test).  The pharmacokinetic parameters were 
compared between them (Table I).  The concentration-time curves of the plasma ara-C 
in the two groups appeared to be similar to each other (Fig. 3 A).  The values for the 
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Cmax, the AUC, and the t1/2 of the plasma ara-C were not different between these 2 
groups.  In contrast, the curve of the intracellular ara-CTP for CR group was drawn 
higher upon the curve for NR group (Fig. 3 B).  The ara-CTP concentrations at all the 
time points including the Cmax were higher in CR group than in NR group although the 
statistical difference was not found (p= 0.13 for the Cmax, Mann-Whitney test).  In 
addition, the ara-CTP was eliminated with the similar t1/2 values in the both groups.  
Consequently, the AUC of the intracellular ara-CTP was significantly greater in CR 
group than in NR group (p=0.02, Mann-Whitney test) (Fig. 4, Table I).     
 
DISCUSSION 
 
   In the present study, we successfully monitored the intracellular ara-CTP 
concentrations during BHAC administration in the combination therapy.  Moreover, we 
evaluated its pharmacokinetics from the viewpoint of the therapeutic efficacy.  The 
ara-CTP pharmacokinetics widely varied among patients, and was not correlated to the 
plasma ara-C concentrations.  The AUC of ara-CTP was significantly greater in CR 
group than in NR group, which was attributed to the higher ara-CTP concentrations 
achieved in patients with CR.       
   As shown in Fig. 1, BHAC maintained both the plasma ara-C and the intracellular 
ara-CTP for a long time.  The t1/2 values of the plasma ara-C and the intracellular 
ara-CTP were longer, even compared with the historical values (2.8 h and 3.4 h, 
respectively) during a 2-h infusion of high-dose ara-C (3 g/m2).31)  BHAC prolonged the 
ara-C retention in the plasma because the drug is resistant to deamination and 
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converted into ara-C slowly.24)  Moreover, we demonstrated in our prior in vitro study 
that the maintenance of ara-C in the medium was crucial to sustaining the intracellular 
ara-CTP in HL 60 leukemic cells.10)  As long as ara-C was present in the extracellular 
fluid, it was transported into the cells and phosphorylated to maintain ara-CTP, whereas 
the intracellular ara-CTP was rapidly eliminated if the extracellular ara-C was washed 
out.10)  Therefore, during BHAC therapy, the maintenance of ara-CTP in leukemic cells 
would be due to the prolonged retention of ara-C in the plasma.  Thus, BHAC 
maintained both the plasma ara-C and the intracellular ara-CTP for a long time.    
   Yoshida et al. evaluated the ara-CTP pharmacokinetics during a 1-h infusion of 
high-dose BHAC (700 mg/m2).32)  In their study, the Cmax, the t1/2 and the AUC of 
ara-CTP were 0.081 µg/107 cells (roughly equal to 20 µM), 13.6 h, and 1.224 µg・h/107 
cells (roughly equal to 250 µM・h), respectively.  These values were compared with our 
pharmacokinetic results of 70 mg/m2 BHAC since in both studies BHAC was similarly 
administered as a short-hour infusion.  To standardize the values, the Cmax and the 
AUC that were produced per 1 mg BHAC were calculated.  The ratio values between 
the Cmax and the dose were 0.029 (calculated by the ratio of 20/700) for Yoshida et al. 
and 0.048 (3.42/70) for ours, which were close to each other.  This ratio represents the 
relative height of the intracellular ara-CTP concentration achieved by 1 mg BHAC.  The 
ratio values between the AUC and the dose were 0.36 (250/700) for Yoshida et al. and 
0.43 (30.76/70) for ours, which were also very similar to each other.  This ratio 
represents the amount of the intracellular ara-CTP produced by 1 mg BHAC, which is 
interpreted as the efficiency of the ara-CTP production.  The t1/2 values for both doses 
were also close to each other.  Thus, these two doses produced ara-CTP with the 
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same efficiency despite the 10-fold difference.  This suggests that ara-CTP would be 
generated in a dose-dependent manner and this ara-CTP production would not be 
saturated by the doses at least up to 700 mg/m2.33)   
   Conventional-dose BHAC is usually used at the doses from 150 to 200 mg/m2.15-17)  
In our protocol, 140 mg/m2 BHAC was used per day.  This dose was divided into 
halves and the half dose (70 mg//m2) was infused twice daily.  Thus, the daily dosage 
(140 mg/m2/day) is regarded to be conventional.  Strictly speaking, we analyzed the 
pharmacokinetics of BHAC at 70 mg//m2, substantially half the conventional dose.  
However, the pharmacokinetic data described in our study would be applicable to the 
conventional dose because the same efficiency of the ara-CTP production was 
suggested at the doses between 70 mg//m2 and 700 mg//m2. 
   ara-CTP has been already reported as a crucial determinant during high-dose ara-C 
therapies (3 g/m2).19-20)  Plunkett et al. demonstrated that the greater AUC of ara-CTP 
was closely correlated to the successful therapeutic outcome during a 2-h infusion of 3 
g/m2 ara-C.19)  They showed that the t1/2 of ara-CTP was significantly longer in patients 
with CR whereas no difference was found in the Cmax between CR and NR groups.  
This suggested that the greater AUC of ara-CTP in CR group was mainly attributed to 
the longer ara-CTP retention in leukemic cells.  On the contrary, in our present BHAC 
study, the AUC of the intracellular ara-CTP was significantly greater in CR group, but 
the t1/2 values were not different between the two groups.  The greater AUC of ara-CTP 
during BHAC therapy was mainly due to the higher ara-CTP concentrations achieved in 
leukemic cells.  It would be difficult to compare directly between these two therapies 
because the drugs, the doses, and the backgrounds of the patients were different from 
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each other.  However, as the intracellular metabolism of ara-C, deoxycytidine kinase is 
thought to be a key enzyme for the production of ara-CTP, while cytidine deaminase is 
regarded to be responsible for the degradation.7, 9, 34)  If so, the mechanism of the drug 
resistance may be different between the 2-h infusions of BHAC and ara-C.  
   In contrast to the intracellular behavior of ara-CTP, no difference was found in the 
plasma ara-C pharmacokinetics between CR and NR groups.  In addition, the total 
doses of BHAC administered through this combination induction therapy were not 
different between the two groups.  In other words, leukemic cells in both groups were 
equally loaded with the same quantity of the AUC of the plasma ara-C in the same 
manner.  Thus, it is suggested that the difference of the ara-CTP production would be 
mainly up to the nature of leukemic cells.   
   The Japan Adult Leukemia Study Group (JALSG) compared the therapeutic effect 
between BHAC and ara-C in the combination induction therapy for AML patients in a 
large cohort study.35)  In that study, conventional-dose ara-C (80 mg/m2) was given as 
a continuous intravenous infusion while 200 mg/m2 BHAC, the equivalent dose of 80 
mg/m2 ara-C, was used as a 3-h intravenous infusion once daily.  The study concluded 
that BHAC resulted in poorer CR and lower event-free survival rates than ara-C.  
Regarding ara-C, however, many pharmacokinetic studies had been previously 
conducted, which revealed that the continuous ara-C infusion produced ara-CTP most 
effectively, and therefore it was the best administration schedule for ara-C.19, 20)  
Conversely, BHAC has been used empirically as a 3-h infusion once daily, only 
because its cytotoxic effect was reported to be independent of the treatment schedule in 
animal tumor models.11, 12, 15-17)  The retrospective analysis of this comparative study 
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also suggested that BHAC was not equivalent to ara-C in terms of the cytotoxic intensity 
despite the premise that the doses of both agents were adjusted to be equivalent by 
their respective molecular weights.36)  At least, our present findings suggest that BHAC 
should be given twice daily because the t1/2 of ara-CTP is almost half a day.  Thus, if 
the better schedule for BHAC is found based on the clinical pharmacokinetics of 
ara-CTP, it may provide a different result for the comparison between BHAC and ara-C.   
   ara-CTP has been reported to be a crucial parameter for the prediction of the 
therapeutic efficacy of high-dose ara-C therapy.19, 20)  On the other hand, the 
importance of ara-CTP has not been clinically confirmed yet with regard to BHAC 
therapy.  This is the first report to relate the clinical pharmacology of ara-CTP to the 
therapeutic response during BHAC treatment.  It would be more accurate to evaluate 
the clinical response of the single therapy of BHAC alone.  But it is difficult because 
BHAC is usually combined with other antileukemic agents in the treatment of AML.  
Nevertheless, the present pharmacokinetic results strongly suggest that intracellular 
ara-CTP concentration can be a predictor for the response to the BHAC–based 
combination therapy.  ara-C is thought to inhibit DNA synthesis partly through the 
inhibition of DNA polymerases by ara-CTP and partly through the incorporation of the 
drug into DNA strands.  Even for the latter, the formation of ara-CTP is essential.  
ara-CTP inhibits DNA polymerases dose-dependently competing with deoxycytidine 
5'-triphosphate.6)  It would be possible to predict the degree of inhibition of DNA 
polymerases by a given ara-CTP concentration from a knowledge of the kinetic 
parameters of DNA polymerases including Michaelis constant and the inhibition 
constant and the intracellular ara-CTP and deoxycytidine triphosphate concentrations. 6, 
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37)  The inhibition constant values for polymerases α and β for ara-CTP are reported to 
be 1.5 µM and 8 µM, respectively in primary AML cells.38)  These in vitro values cannot 
be directly translated in the clinical situation.6)  However, it is suggested that individual 
leukemic cells might have a target ara-CTP concentration for the maximal inhibition of 
DNA synthesis.  Thus, for the maximal therapeutic effects, the optimal administration 
schedule for BHAC may be directed by the intracellular ara-CTP pharmacokinetics in 
each patient. 
 
ACKNOWLEDGMENTS 
 
   This work was supported in part by a Grant-in-Aid from the Ministry of Health and 
Welfare, Japan.  We thank Ms. Shinobu Niwa for her technical assistance.  
- 14 –  
  
REFERENCES 
 
1) 
Berman, E. Chemotherapy in acute myelogenous leukemia: high dose, higher 
expectations? J. Clin. Oncol., 13, 1-4 (1995).  
2)  
Rowe, J. M. What is the best induction regimen for acute myelogenous leukemia? 
Leukemia, 12 (Suppl. 1), S16-S19 (1998). 
3) 
Fukushima, T. and Ueda, T. Current situation and perspective for treatment of acute 
myelogenous leukemia in adults. Jpn. J. Cancer. Chemother., 25, 295-302 (1998) (in 
Japanese). 
4) 
Chou, T.-C., Hutchinson, D. J., Schmid, F. A. and Philips, F. S. Metabolism and 
selective effects of 1-β-D-arabinofuranosylcytosine in L1210 and host tissues in vivo. 
Cancer Res., 35, 225-236 (1975). 
5) 
Graham, F. L. and Whitmore, G. F. The effect of 1-β-D-arabinofuranosylcytosine on 
growth, viability, and DNA synthesis of mouse L-cells. Cancer Res., 30, 2627-2635 
(1970). 
6) 
Graham, F. L. and Whitmore, G. F. Studies in mouse L-cells on the incorporation of 
1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 
- 15 –  
  
1-β-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res., 30, 2636-2644 (1970).  
7) 
Chou, T.-C., Arlin, Z., Clarkson, B. D. and Philips, F. S. Metabolism of 
1-β-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res., 37, 3561-3570 
(1977). 
8) 
Spriggs, D., Robbins, G., Ohno, Y. and Kufe, D. Detection of 
1-β-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res., 47, 
6532-6536 (1987). 
9) 
Ozawa, S., Sugiyama, Y., Mitsuhashi, J. and Inaba, M. Kinetic analysis of cell killing 
effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase 
specificity in human colon cancer and Chinese hamster cells. Cancer Res., 49, 
3823-3828 (1989). 
10) 
Kamiya, K., Uchida, M., Ueda, T. and Nakamura, T. Studies on intracellular kinetics of 
ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable 
administration of ara-C. J. Jpn. Soc. Cancer. Ther., 25, 1419-1427 (1990) (in 
Japanese).  
11) 
Aoshima, M., Tsukagoshi, S., Sakurai,Y., Oh-ishi, J., Ishida, T. and Kobayashi, H. 
Antitumor activities of newly synthesized N4-acyl-1-β-D-arabinofuranosylcytosine. 
Cancer Res., 36, 2726-2732 (1976). 
- 16 –  
  
12) 
Aoshima, M., Tsukagoshi, S., Sakurai, Y., Oh-ishi, J., Ishida, T. and Kobayashi, H. 
N4-Behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent. 
Cancer Res., 37, 2481-2486 (1977).  
13) 
Ueda, T., Nakamura, T., Kagawa, D., Uchida, M., Domae, N., Sugiyama, M., Ueda, Y., 
Sasada, M. and Uchino, H. Clinical pharmacology of 
N4-palmitoyl-1-β-D-arabinofuranosylcytosine in patients with hematologic malignancies. 
Cancer Chemother. Pharmacol., 24, 371-375 (1989). 
14) 
Ueda, T., Kamiya, K., Urasaki, Y., Wataya, S., Kawai, Y., Tsutani, H., Sugiyama, M. and 
Nakamura, T. Clinical pharmacology of 
1-β-D-arabinofuranosylcytosine-5’-stearylphosphate, an orally administered long-acting 
derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res., 54, 109-113 
(1994). 
15) 
Kimura, K., Ohno, R., Amaki, I., Hattori, K., Hirota, Y., Hoshino, A., Ichimaru, M., Ito, M., 
Kimura, I., Maekawa, T., Masaoka, T., Nakamura, T., Ogawa, M., Oguro, M., Ohta, K., 
Osamura, S., Shimoyama, M., Takaku, F., Uzuka, Y. and Yamada, K. Treatment of 
acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine. 
Cancer, 56, 1913-1917 (1985). 
16) 
Ohno, R., Kato, Y., Nagura, E., Murase, T., Okumura, M., Yamada, H., Ogura, M., 
- 17 –  
  
Minami, S., Suzuki, H., Morishima, Y., Yokomaku, S., Ezaki, K., Kodera, Y., Kawashima, 
K., Saito, H. and Yamada, K. Behenoyl cytosine arabinoside, daunorubicin, 
6-mercaptopurine, and prednisolone combination therapy for acute myelogenous 
leukemia in adults and prognostic factors related to remission duration and survival 
length. J. Clin. Oncol., 4, 1740-1747 (1986). 
17) 
Yoshida, M., Suda, K., Tsuboyama, A., Sasaki, R., Kitagawa, S., Kano, Y., Muto, Y., 
Takaku, F., Sakamoto, S. and Miura, Y. Behenoyl cytosine arabinoside, aclacinomycin 
A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic 
leukemia in adults. Eur. J. Haematol., 43, 1-6 (1989). 
18) 
Higashigawa, M., Ochiai, H., Ohkubo, T., Kawasaki, H., Nobori, T., kamiya, H. and 
Sakurai, M. Incorporation of N4-behenoyl-1-β-D-arabinofuranosylcytosine into DNA as 
1-β-D-arabinofuranosylcytosine. Med. Oncol. Tumor Pharmacother., 5, 265-271 (1988).  
19) 
Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Liliemark, J. O. and Keating, M.J. 
Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol., 12 
(suppl. 3), 20-30 (1985). 
20) 
Heinemann, V., Estey, E., Keating, M. J. and Plunkett, W. Patient-specific dose rate for 
continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J. 
Clin. Oncol., 7, 622-628 (1989). 
21) 
- 18 –  
  
Plunkett, W., Hug, V., Keating, M. J. and Chubb, S. Quantitation of 
1-β-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow 
and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. 
Cancer Res., 40, 588-591 (1980). 
22) 
Yamada, K., Kawashima, K., Kato, Y., Morishima, Y., Tanimoto, M. and Ohno, R. 
Pharmacology and clinical studies of N4-behenoyl-1-β-D-arabinofuranosylcytosine. 
Recent Results Cancer Res., 70, 219-229 (1980). 
23) 
Kimura, K., Ohno, R., Amaki, I., Hattori, K., Hirota, Y., Hoshino, A., Ichimaru, M., Ito, M., 
Kimura, I., Maekawa, T., Masaoka, T., Nakamura, T., Ogawa, M., Oguro, M., Ohta, K., 
Osamura, S., Shimoyama, M., Takaku, F., Uzuka, Y. and Yamada, K. Phase I clinical 
and pharmacokinetic study of N4-behenoyl-1-β-D-arabinofuranosylcytosine. Med. Oncol. 
Tumor Pharmacother., 3, 15-24 (1986). 
24) 
Ueda, T., Nakamura, T., Ando, S., Kagawa, D., Sasada, M., Uchino, H., Johno, I. and 
Akiyama, Y. Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in 
patients with acute leukemia. Cancer Res., 43, 3412-3416 (1983). 
25) 
Yamauchi, T., Ueda, T. and Nakamura, T. A new sensitive method for determination of 
intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate content in human materials 
in vivo. Cancer Res., 56, 1800-1804 (1996). 
26) 
- 19 –  
  
Yamauchi, T., Kawai, Y., Kishi, S., Goto, N., Urasaki, Y., Imamura, S., Fukushima, T., 
Yoshida, A., Iwasaki, H., Tsutani, H., Masada, M. and Ueda, T. Monitoring of 
intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate in 
1-β-D-arabinofuranosylcytosine therapy at low and conventional doses. Jpn. J. Cancer 
Res., 92, 546-553 (2001). 
27) 
Shimada, N., Ueda, T., Yokoshima, T., Oh-ishi, J. and Oh-oka, T. A sensitive and 
specific radioimmunoassay for 1-β-D-arabino-furanosylcytosine. Cancer Lett., 24, 
173-178 (1984). 
28) 
Ho, D. H. W. and Frei, E., III. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. 
Clin. Pharmacol. Ther., 12, 944-954 (1971).  
29) 
Fallon, H. J., Frei, E., III, Davidson, J. D., Trier, J. S. and Burk, D. Leukocyte 
preparations from human blood: evaluation of their morphologic and metabolic state. J. 
Lab. Clin. Med., 59, 779-791 (1962).  
30) 
Yamaoka, K., Nakagawa, T. and Uno, T. Statistical moments in pharmacokinetics. J. 
Pharmacokinet. Biopharm., 6, 547-558 (1978).  
31) 
Liliemark, J. O., Plunkett, W. and Dixon, D. O. Relationship of 
1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 
5'-triphosphate levels in leukemic cells during treatment with high-dose 
- 20 –  
  
1-β-D-arabinofuranosylcytosine. Cancer Res., 45, 5952-5957 (1985).  
32) 
Yoshida, T., Kobayashi, K., Okabe, Y., Okumura, H., Matano, S., Kanno, M., Takeda, Y., 
Ohtake, S., Nakamura, S. and Matsuda, T. Plasma and leukemic cell pharmacokinetics 
of high-dose N4-behenoyl-1-β-D-arabinofuranosylcytosine in acute leukemia patients. J. 
Clin. Pharmacol., 34, 52-59 (1994). 
33) 
Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H. and 
Keating, M. J. Saturation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate 
accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. 
Cancer Res., 47, 3005-3011 (1987). 
34) 
Momparler, R. L. A model for the chemotherapy of acute leukemia with 
1-β-D-arabinofuranosylcytosine. Cancer Res., 34, 1775-1787 (1974). 
35) 
Kobayashi, T., Miyawaki, S., Tanimoto, M., Kuriyama, K., Murakami, H., Yoshida, M., 
Minami, S., Minato, K., Tsubaki, K., Ohmoto, E., Oh, H., Jinnai, I., Sakamaki, H., 
Hiraoka, A., Kanamaru, A., Takahashi, I., Saito, K., Naoe, T., Yamada, O., Asou, N., 
Kageyama, S., Emi, N., Matsuoka, A., Tomonaga, M., Saito, H., Ueda, R. and Ohno, R. 
Randomized trials between behenoyl cytarabine and cytarabine in combination 
induction and consolidation therapy, and with or without ubenimex after 
maintenance/intensification therapy in adult acute myeloid leukeimia.  J.Clin. Oncol., 
14, 204-213 (1996). 
- 21 –  
  
36) 
Miyawaki, S., Kobayashi, T., Tanimoto, M., Kuriyama, K., Murakami, H., Yoshida, M., 
Minami, S., Minato, K., Tsubaki, K., Omoto, E., Oh, H., Jinnai, I., Sakamaki, H., Hiraoka, 
A., Kanamaru, A., Takahashi, I., Saito, K., Naoe, T., Yamada, O., Asou, N., Kageyama, 
S., Emi, N., Ueda, T., Tomonaga, M., Saito, H., Ueda, R. and Ohno, R.  Comparison of 
leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 
consolidation therapy. Int. J. Hematol., 70, 56-57 (1999). 
37) 
Wang, L.-M., White, J. C., and Capizzi, R. L. The effect of ara-C-induced inhibition of 
DNA synthesis on its cellular pharmacology. Cancer Chemother. Pharmacol., 25, 
418-424 (1990).  
38) 
Townsend, A. J., and Cheng, Y.-C. Sequence-specific effects of ara-5-aza-CTP and 
ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of 
chain elongation on a defined template.  Mol. Pharmacol., 32, 330-339 (1987). 
 
 
 
- 22 –  
  
LEGENDS 
 
Fig. 1.  Mean ± SD concentration-time curves of the plasma ara-C (A) and the 
intracellular ara-CTP (B) in 11 acute myelogenous leukemia patients who received the 
2-h intravenous infusion of 70 mg/m2 BHAC.   
Fig. 2.  Relationship of the Cmax (A) or the AUC (B) between the plasma ara-C and the 
intracellular ara-CTP.   
Fig. 3.  Mean concentration-time curves of the plasma ara-C (A) and the intracellular 
ara-CTP (B) in CR group (7 patients) and NR group (4 patients) receiving the 2-h 
intravenous infusion of 70 mg/m2 BHAC.  Closed circles: CR group; open circles: NR 
group; 
Fig. 4.  Comparison of the AUC of the plasma ara-C (A) or the intracellular ara-CTP 
(B) between CR group (7 patients) and NR group (4 patients).   
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